News | SCAI | May 01, 2024

Groundbreaking Data in Interventional Cardiology to be Featured at Society for Cardiovascular Angiology and Interventions SCAI 2024 Scientific Sessions

The Society for Cardiovascular Angiography & Interventions (SCAI) kicks off its SCAI Scientific Sessions 2024 this week, May 2-4 in Long Beach, CA, bringing together more than 1,800 clinicians, scientists, researchers, and innovators in the field of interventional cardiology and endovascular medicine for late-breaking science on PCI, TAVR, PAD and heart valve studies.

The Society for Cardiovascular Angiography & Interventions (SCAI) kicks off its SCAI Scientific Sessions 2024 this week, May 2-4 in Long Beach, CA, bringing together more than 1,800 clinicians, scientists, researchers, and innovators in the field of interventional cardiology and endovascular medicine.

The Society for Cardiovascular Angiography & Interventions (SCAI) kicks off its SCAI Scientific Sessions 2024 this week, May 2-4 in Long Beach, CA, bringing together more than 1,800 clinicians, scientists, researchers, and innovators in the field of interventional cardiology and endovascular medicine. Image courtesy: Long Beach Convention Center


May 1, 2024 — The annual Society for Cardiovascular Angiography & Interventions (SCAI) kicks off its SCAI Scientific Sessions 2024 this week, May 2-4 in Long Beach, CA, and organizers report the annual meeting will bring together more than 1,800 clinicians, scientists, researchers, and innovators in the field of interventional cardiology and endovascular medicine.

“We are proud to offer over 80 sessions in a variety of interactive educational formats at this year’s meeting. We believe the tools, resources, and information shared at the meeting will provide the healthcare community with greater expertise to improve patient outcomes and also connect with their interventional cardiology colleagues,” said SCAI President George D. Dangas, MD, PhD, MSCAI, Icahn School of Medicine - Mt. Sinai Hospital (New York, NY).

Presenting the latest cutting-edge advances in cardiovascular research, prevention, and care will be 500+ faculty, nearly 450 abstracts presenting the latest clinical data, procedural guidance, and advanced expertise, according to the organization, which offered the following snapshot summary.

Heart disease has been the leading cause of death in the United States since 1950, and as one of the most prevalent health conditions, impacting half of all Americans. According to the Centers for Disease Control and Prevention (CDC), heart disease and stroke rank as the first and fifth leading causes of death in the nation. These conditions affect millions of individuals across the country each year, with more than 877,500 Americans experiencing symptoms related to heart disease, stroke, or other cardiovascular diseases annually. This prevalence underscores the urgent need for heightened awareness, prevention strategies, and access to quality healthcare services to combat the detrimental effects of cardiovascular diseases on public health.

“At this year’s SCAI Scientific Sessions, we are seeing a broad range of clinical trials and emerging science all with the same aim – improving patient outcomes and experience. Featuring numerous abstracts with fresh insights into health disparities, efficacy data for TAVR, and innovative strategies for PAD, we eagerly anticipate the convergence of professionals from diverse specialties. Their teamwork and collaboration, allows us to advance collective efforts within this sector, driving forward innovation and enhancing patient care," said SCAI Interventional Cardiology Program Chair, J. Dawn Abbott, MD, FSCAI, Lifespan Cardiovascular Institute.     

Late-Breaking Cardiovascular Clinical Trials: PCI, TAVR, PAD in the Spotlight

New Research: As a common non-surgical procedure used to treat blockages in a coronary artery, around 900,000 percutaneous coronary interventions (PCIs) are performed every year in the U.S. This new study looks at the trends and clinical outcomes with radial versus femoral arterial access for PCIs.

Late-breaking oral presentation: Temporal Trends and Clinical Outcomes with Radial Versus Femoral Arterial Access for Percutaneous Coronary Intervention in the US (Date and Time: Thursday, May 2 9:17-9:24 AM PT)

Transcatheter Aortic Valve Replacement (TAVR): TAVR is a minimally-invasive procedure to replace an aortic valve that is narrowed and doesn't open fully, which can help reduce chest pain, shortness of breath and other symptoms of aortic valve stenosis. About 276,000 patients have undergone a TAVR procedure in the United States. This year’s meetings will feature presentations focusing on TAVR including:

Late-breaking oral presentation: Self-Expanding Versus Balloon-Expandable Transcatheter Aortic Valve Replacement in Patients with Small Aortic Annuli: Additional Outcomes from the SMART Trial (Date and Time: Friday, May 3 2:44-2:51 PM PT)

Late-breaking oral presentation: Self Update from the First-in-human study with the novel DurAVR biomimetic transcatheter heart valve (Date and Time: Friday, May 3 10:55-11:00 AM PT)

Peripheral Artery Disease (PAD): According to a recent survey, 70% of Americans are unaware of PAD – the most common vascular disease in which leg arteries become narrowed, reducing or cutting off blood flow. PAD contributes to 400 amputations each day.

This year’s meetings will feature several studies addressing PAD including:

Late-breaking oral presentation: Revascularization strategies in patients with peripheral arterial disease involving the femoropopliteal arteries: A pooled analysis of individual patient data (Date and Time: Friday, May 3:12-3:19 PM PT)

More information: www.scai.org

Find more SCAI24 conference coverage here

 


Related Content

News | SCAI

May 3, 2025 — The Society for Cardiovascular Angiography & Interventions (SCAI) announced its new leadership for 2025–26 ...

Home May 05, 2025
Home
News | SCAI

At the SCAI 2025 Scientific Sessions in Washington, DC, SCAI President James B. Hermiller, MD, MSCAI, recognized several ...

Home May 01, 2025
Home
News | SCAI

Feb. 12, 2025 — A new study published in JSCAI has revealed a lower risk of cardiovascular events for patients with Type ...

Home February 18, 2025
Home
News | SCAI

May 7, 2024 — Medtronic announced the release of important clinical outcomes in two leading transcatheter valve ...

Home May 07, 2024
Home
News | SCAI

May 7, 2024 — Women and black patients were less frequently treated with minimally invasive therapy compared to men or ...

Home May 07, 2024
Home
News | SCAI

June 1, 2023 — New insights from the TWILIGHT trial showed that ticagrelor monotherapy after three months of ticagrelor ...

Home June 01, 2023
Home
News | SCAI

May 24, 2023 — The largest interventional study focused on pulmonary embolisms highlighted importance of rapid removal ...

Home May 24, 2023
Home
Feature | SCAI | Christine Book

May 23, 2023 — The Society for Cardiovascular Angiography & Interventions (SCAI) welcomed its 46th President and 2023 ...

Home May 23, 2023
Home
News | SCAI

May 19, 2023 — Findings from a study examining the relationship between marijuana use and peripheral artery disease (PAD ...

Home May 19, 2023
Home
News | SCAI

February 7, 2023 — The Society for Cardiovascular Angiography & Interventions (SCAI) announced the second application ...

Home February 07, 2023
Home
Subscribe Now